Loading…
Intravenous immunoglobulin in HIV infection: evidence for the efficacy of treatment
Eight children with symptoms of HIV infection were treated for 12-26 months (median 14 months) with infusions of intravenous immunoglobulin (200 mg/kg) every three weeks. Significant improvement was noted in all children in terms of weight gain, number of infectious episodes, and days spent in hospi...
Saved in:
| Published in: | Archives of disease in childhood 1989-08, Vol.64 (8), p.1146-1150 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-b541t-b8e0ba4d2e8492e99d307ea453c2e1260bf71a58d82c450a846a3c08b97fb3a3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-b541t-b8e0ba4d2e8492e99d307ea453c2e1260bf71a58d82c450a846a3c08b97fb3a3 |
| container_end_page | 1150 |
| container_issue | 8 |
| container_start_page | 1146 |
| container_title | Archives of disease in childhood |
| container_volume | 64 |
| creator | Hague, R A Yap, P L Mok, J Y Eden, O B Coutts, N A Watson, J G Hargreaves, F D Whitelaw, J M |
| description | Eight children with symptoms of HIV infection were treated for 12-26 months (median 14 months) with infusions of intravenous immunoglobulin (200 mg/kg) every three weeks. Significant improvement was noted in all children in terms of weight gain, number of infectious episodes, and days spent in hospital. This resulted in a 49% saving in cost on treatment compared with costs accrued previously during inpatient admissions. Immunoglobulin concentrations, which were raised at the start of treatment were not altered, and T4 counts continued to decline slowly. HIV core antigen was detected in four children before treatment, but all became core antigen negative after treatment was commenced, this effect being sustained in three. Intravenous immunoglobulin therefore has major clinical benefit, and by reducing viral activity may delay disease progression. |
| doi_str_mv | 10.1136/adc.64.8.1146 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1792533</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79214690</sourcerecordid><originalsourceid>FETCH-LOGICAL-b541t-b8e0ba4d2e8492e99d307ea453c2e1260bf71a58d82c450a846a3c08b97fb3a3</originalsourceid><addsrcrecordid>eNqFkc1rFDEYxoModVs9ehQGFPEya75mJvEgyFLbpUsVLcVbyGTetFlnkprMLPa_N8suS_VSEvISnh_v14PQK4LnhLD6g-7MvOZzkX-8foJm-RUlxZw_RTOMMSulEOI5Ok5pjTGhQrAjdEQbQSUVM_Rj6ceoN-DDlAo3DJMPN31op975It_z5XUOFszogv9YwMZ14A0UNsRivIUCrHVGm_si2GKMoMcB_PgCPbO6T_ByH0_Q1ZfTq8V5ufp6tlx8XpVtxclYtgJwq3lHQXBJQcqO4QY0r5ihQGiNW9sQXYlOUMMrrAWvNTNYtLKxLdPsBH3apb2b2gE6A9tJenUX3aDjvQraqX8V727VTdgo0khaMZYTvNsniOH3BGlUg0sG-l57yOtQGcvLlPhRkOR5cD4ZfPMfuA5T9HkJighRC0YkrTNV7igTQ0oR7KFngtXWU5U9VTVXQm09zfzrh4Me6L2JWX-713UyurdRe-PSAWsYlax6UNalEf4cZB1_qbphTaUurxeq-XZ59n118VNdZP79jm-H9SMd_gXUgcYu</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1886831926</pqid></control><display><type>article</type><title>Intravenous immunoglobulin in HIV infection: evidence for the efficacy of treatment</title><source>Social Science Premium Collection</source><source>PubMed Central</source><source>Education Collection</source><creator>Hague, R A ; Yap, P L ; Mok, J Y ; Eden, O B ; Coutts, N A ; Watson, J G ; Hargreaves, F D ; Whitelaw, J M</creator><creatorcontrib>Hague, R A ; Yap, P L ; Mok, J Y ; Eden, O B ; Coutts, N A ; Watson, J G ; Hargreaves, F D ; Whitelaw, J M</creatorcontrib><description>Eight children with symptoms of HIV infection were treated for 12-26 months (median 14 months) with infusions of intravenous immunoglobulin (200 mg/kg) every three weeks. Significant improvement was noted in all children in terms of weight gain, number of infectious episodes, and days spent in hospital. This resulted in a 49% saving in cost on treatment compared with costs accrued previously during inpatient admissions. Immunoglobulin concentrations, which were raised at the start of treatment were not altered, and T4 counts continued to decline slowly. HIV core antigen was detected in four children before treatment, but all became core antigen negative after treatment was commenced, this effect being sustained in three. Intravenous immunoglobulin therefore has major clinical benefit, and by reducing viral activity may delay disease progression.</description><identifier>ISSN: 0003-9888</identifier><identifier>EISSN: 1468-2044</identifier><identifier>DOI: 10.1136/adc.64.8.1146</identifier><identifier>PMID: 2782928</identifier><identifier>CODEN: ADCHAK</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health</publisher><subject>Acquired Immunodeficiency Syndrome - complications ; Acquired Immunodeficiency Syndrome - immunology ; Acquired Immunodeficiency Syndrome - therapy ; AIDS/HIV ; Biological and medical sciences ; Child, Preschool ; Follow-Up Studies ; HIV Antigens - analysis ; Hospitalization ; Humans ; Immunization, Passive ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Infant ; Infusions, Intravenous ; Medical sciences ; Time Factors</subject><ispartof>Archives of disease in childhood, 1989-08, Vol.64 (8), p.1146-1150</ispartof><rights>1989 INIST-CNRS</rights><rights>Copyright BMJ Publishing Group LTD Aug 1989</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b541t-b8e0ba4d2e8492e99d307ea453c2e1260bf71a58d82c450a846a3c08b97fb3a3</citedby><cites>FETCH-LOGICAL-b541t-b8e0ba4d2e8492e99d307ea453c2e1260bf71a58d82c450a846a3c08b97fb3a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1886831926/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1886831926?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,21358,21374,27903,27904,33590,33591,33856,33857,43712,43859,53769,53771,73967,74143</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7329356$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2782928$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hague, R A</creatorcontrib><creatorcontrib>Yap, P L</creatorcontrib><creatorcontrib>Mok, J Y</creatorcontrib><creatorcontrib>Eden, O B</creatorcontrib><creatorcontrib>Coutts, N A</creatorcontrib><creatorcontrib>Watson, J G</creatorcontrib><creatorcontrib>Hargreaves, F D</creatorcontrib><creatorcontrib>Whitelaw, J M</creatorcontrib><title>Intravenous immunoglobulin in HIV infection: evidence for the efficacy of treatment</title><title>Archives of disease in childhood</title><addtitle>Arch Dis Child</addtitle><description>Eight children with symptoms of HIV infection were treated for 12-26 months (median 14 months) with infusions of intravenous immunoglobulin (200 mg/kg) every three weeks. Significant improvement was noted in all children in terms of weight gain, number of infectious episodes, and days spent in hospital. This resulted in a 49% saving in cost on treatment compared with costs accrued previously during inpatient admissions. Immunoglobulin concentrations, which were raised at the start of treatment were not altered, and T4 counts continued to decline slowly. HIV core antigen was detected in four children before treatment, but all became core antigen negative after treatment was commenced, this effect being sustained in three. Intravenous immunoglobulin therefore has major clinical benefit, and by reducing viral activity may delay disease progression.</description><subject>Acquired Immunodeficiency Syndrome - complications</subject><subject>Acquired Immunodeficiency Syndrome - immunology</subject><subject>Acquired Immunodeficiency Syndrome - therapy</subject><subject>AIDS/HIV</subject><subject>Biological and medical sciences</subject><subject>Child, Preschool</subject><subject>Follow-Up Studies</subject><subject>HIV Antigens - analysis</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Immunization, Passive</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Infant</subject><subject>Infusions, Intravenous</subject><subject>Medical sciences</subject><subject>Time Factors</subject><issn>0003-9888</issn><issn>1468-2044</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>ALSLI</sourceid><sourceid>CJNVE</sourceid><sourceid>M0P</sourceid><recordid>eNqFkc1rFDEYxoModVs9ehQGFPEya75mJvEgyFLbpUsVLcVbyGTetFlnkprMLPa_N8suS_VSEvISnh_v14PQK4LnhLD6g-7MvOZzkX-8foJm-RUlxZw_RTOMMSulEOI5Ok5pjTGhQrAjdEQbQSUVM_Rj6ceoN-DDlAo3DJMPN31op975It_z5XUOFszogv9YwMZ14A0UNsRivIUCrHVGm_si2GKMoMcB_PgCPbO6T_ByH0_Q1ZfTq8V5ufp6tlx8XpVtxclYtgJwq3lHQXBJQcqO4QY0r5ihQGiNW9sQXYlOUMMrrAWvNTNYtLKxLdPsBH3apb2b2gE6A9tJenUX3aDjvQraqX8V727VTdgo0khaMZYTvNsniOH3BGlUg0sG-l57yOtQGcvLlPhRkOR5cD4ZfPMfuA5T9HkJighRC0YkrTNV7igTQ0oR7KFngtXWU5U9VTVXQm09zfzrh4Me6L2JWX-713UyurdRe-PSAWsYlax6UNalEf4cZB1_qbphTaUurxeq-XZ59n118VNdZP79jm-H9SMd_gXUgcYu</recordid><startdate>19890801</startdate><enddate>19890801</enddate><creator>Hague, R A</creator><creator>Yap, P L</creator><creator>Mok, J Y</creator><creator>Eden, O B</creator><creator>Coutts, N A</creator><creator>Watson, J G</creator><creator>Hargreaves, F D</creator><creator>Whitelaw, J M</creator><general>BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health</general><general>BMJ</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88B</scope><scope>88E</scope><scope>88I</scope><scope>8A4</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>CJNVE</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0P</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEDU</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19890801</creationdate><title>Intravenous immunoglobulin in HIV infection: evidence for the efficacy of treatment</title><author>Hague, R A ; Yap, P L ; Mok, J Y ; Eden, O B ; Coutts, N A ; Watson, J G ; Hargreaves, F D ; Whitelaw, J M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b541t-b8e0ba4d2e8492e99d307ea453c2e1260bf71a58d82c450a846a3c08b97fb3a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Acquired Immunodeficiency Syndrome - complications</topic><topic>Acquired Immunodeficiency Syndrome - immunology</topic><topic>Acquired Immunodeficiency Syndrome - therapy</topic><topic>AIDS/HIV</topic><topic>Biological and medical sciences</topic><topic>Child, Preschool</topic><topic>Follow-Up Studies</topic><topic>HIV Antigens - analysis</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Immunization, Passive</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Infant</topic><topic>Infusions, Intravenous</topic><topic>Medical sciences</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hague, R A</creatorcontrib><creatorcontrib>Yap, P L</creatorcontrib><creatorcontrib>Mok, J Y</creatorcontrib><creatorcontrib>Eden, O B</creatorcontrib><creatorcontrib>Coutts, N A</creatorcontrib><creatorcontrib>Watson, J G</creatorcontrib><creatorcontrib>Hargreaves, F D</creatorcontrib><creatorcontrib>Whitelaw, J M</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Education Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Education Periodicals</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Education Collection</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Education Database</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Education</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Archives of disease in childhood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hague, R A</au><au>Yap, P L</au><au>Mok, J Y</au><au>Eden, O B</au><au>Coutts, N A</au><au>Watson, J G</au><au>Hargreaves, F D</au><au>Whitelaw, J M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravenous immunoglobulin in HIV infection: evidence for the efficacy of treatment</atitle><jtitle>Archives of disease in childhood</jtitle><addtitle>Arch Dis Child</addtitle><date>1989-08-01</date><risdate>1989</risdate><volume>64</volume><issue>8</issue><spage>1146</spage><epage>1150</epage><pages>1146-1150</pages><issn>0003-9888</issn><eissn>1468-2044</eissn><coden>ADCHAK</coden><abstract>Eight children with symptoms of HIV infection were treated for 12-26 months (median 14 months) with infusions of intravenous immunoglobulin (200 mg/kg) every three weeks. Significant improvement was noted in all children in terms of weight gain, number of infectious episodes, and days spent in hospital. This resulted in a 49% saving in cost on treatment compared with costs accrued previously during inpatient admissions. Immunoglobulin concentrations, which were raised at the start of treatment were not altered, and T4 counts continued to decline slowly. HIV core antigen was detected in four children before treatment, but all became core antigen negative after treatment was commenced, this effect being sustained in three. Intravenous immunoglobulin therefore has major clinical benefit, and by reducing viral activity may delay disease progression.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health</pub><pmid>2782928</pmid><doi>10.1136/adc.64.8.1146</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-9888 |
| ispartof | Archives of disease in childhood, 1989-08, Vol.64 (8), p.1146-1150 |
| issn | 0003-9888 1468-2044 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1792533 |
| source | Social Science Premium Collection; PubMed Central; Education Collection |
| subjects | Acquired Immunodeficiency Syndrome - complications Acquired Immunodeficiency Syndrome - immunology Acquired Immunodeficiency Syndrome - therapy AIDS/HIV Biological and medical sciences Child, Preschool Follow-Up Studies HIV Antigens - analysis Hospitalization Humans Immunization, Passive Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infant Infusions, Intravenous Medical sciences Time Factors |
| title | Intravenous immunoglobulin in HIV infection: evidence for the efficacy of treatment |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T11%3A57%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravenous%20immunoglobulin%20in%20HIV%20infection:%20evidence%20for%20the%20efficacy%20of%20treatment&rft.jtitle=Archives%20of%20disease%20in%20childhood&rft.au=Hague,%20R%20A&rft.date=1989-08-01&rft.volume=64&rft.issue=8&rft.spage=1146&rft.epage=1150&rft.pages=1146-1150&rft.issn=0003-9888&rft.eissn=1468-2044&rft.coden=ADCHAK&rft_id=info:doi/10.1136/adc.64.8.1146&rft_dat=%3Cproquest_pubme%3E79214690%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b541t-b8e0ba4d2e8492e99d307ea453c2e1260bf71a58d82c450a846a3c08b97fb3a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1886831926&rft_id=info:pmid/2782928&rfr_iscdi=true |